Clinical Outcome Assessments Toolbox for Radiopharmaceuticals.
Publication/Presentation Date
1-1-2019
Abstract
For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The NCI's planned scope for HRQOL, symptom and patient-reported outcomes management research is explained as it pertains to radiopharmaceutical clinical development. An effort already underway to support protocol authoring via an NCI Cancer Therapy Evaluation Program (CTEP) Centralized Protocol Writing Service (CPWS) is described as this service aids incorporation of HRQOL, symptom and patient-reported outcomes management research into sponsored protocols.
Volume
9
First Page
1028
Last Page
1028
ISSN
2234-943X
Published In/Presented At
Kunos, C. A., Capala, J., Dicker, A. P., Movsas, B., Ivy, S. P., & Minasian, L. M. (2019). Clinical Outcome Assessments Toolbox for Radiopharmaceuticals. Frontiers in oncology, 9, 1028. https://doi.org/10.3389/fonc.2019.01028
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31649885
Department(s)
Administration and Leadership
Document Type
Article